secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017458
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera reports Q1 net loss of $40.9M, cash $516M; initiates MDM2 degrader trial
-------------------------------------------------------------------------------

- Net loss $40.9M vs $36.7M Q1 2022; R&D expenses $42.2M (up from $35.9M).
- Cash and investments $516M as of March 31, 2023; runway into H2 2025.
- Phase 1 trial of MDM2 degrader KT-253 initiated in relapsed/refractory myeloid malignancies and solid tumors.
- KT-474 (IRAK4 degrader) Phase 2 planned in hidradenitis suppurativa for 2023; Phase 1 data at EADV May 18.
- KT-333 and KT-413 Phase 1 updates at ICML in June; anti-tumor activity data expected later in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000095017023017458/0000950170-23-017458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000095017023017458/kymr-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer